NCT00272415View on ClinicalTrials.gov

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2005

Conditions
Melanoma
Interventions
DRUG

INO-1001

Intravenous repeating dose

DRUG

temozolomide

Oral repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY